The earnings call highlighted significant progress in clinical studies and reduced financial losses compared to the previous year. However, concerns about limited cash reserves and some dose-limiting toxicities in the AML triplet study were noted. Overall, the sentiment leans towards positive due to the promising clinical results and improved financial performance.

Company Guidance

During the Curis Third Quarter 2025 Business Update Conference Call, the company provided guidance on several key metrics and strategic initiatives. Curis is focusing on the development of emavusertib in combination with ibrutinib for treating primary CNS lymphoma, with plans to support accelerated submissions in the U.S. and Europe over the next 12 to 18 months. They are also initiating a proof-of-concept study for CLL patients on BTKi monotherapy, aiming to enroll the first patient by late Q4 2025 or early Q1 2026, with initial data expected at the ASH Annual Meeting in December 2026. In the AML triplet study, emavusertib showed promising results, with MRD conversion to undetectable levels in 4 of 8 evaluable patients. Financially, Curis reported a net loss of $7.7 million for Q3 2025, an improvement from a $10.1 million loss in the same period in 2024, with $9.1 million in cash and cash equivalents as of September 30, 2025. The company aims to secure additional capital to support its ongoing programs, emphasizing their focus on PCNSL and the new CLL trial.

Progress in TakeAim Lymphoma Study

Steady progress in the TakeAim Lymphoma study, evaluating emavusertib in combination with ibrutinib, with expectations for accelerated submissions in the U.S. and Europe.

Promising Initial Results in AML Triplet Study

MRD conversion to undetectable levels occurred in 4 of 8 evaluable patients within 5 to 8 weeks in AML triplet study, with no disease progression observed.

Reduced Net Loss

Net loss for Q3 2025 was $7.7 million compared to $10.1 million for the same period in 2024. For the 9 months ended September 30, 2025, the net loss was $26.9 million compared to $33.8 million in 2024.

Lower R&D and Administrative Expenses

R&D expenses were $6.4 million for Q3 2025 compared to $9.7 million in Q3 2024, and administrative expenses were $3.7 million compared to $3.8 million in the same period.

Curis (CRIS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CRIS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 17, 2026	2025 (Q4)	-0.45 / -	-1.25	―	―	―
Nov 06, 2025	2025 (Q3)	-0.58 / -0.49	-1.7	71.18% (+1.21)	―
Aug 05, 2025	2025 (Q2)	-1.36 / -0.68	-2.03	66.50% (+1.35)	―
May 06, 2025	2025 (Q1)	- / 1.25	-2.05	160.98% (+3.30)	―
Mar 31, 2025	2024 (Q4)	-1.11 / -1.25	-2.05	39.02% (+0.80)	―
Nov 14, 2024	2024 (Q3)	-1.83 / -1.70	-2.13	20.19% (+0.43)	―
Aug 01, 2024	2024 (Q2)	-1.79 / -2.03	-2.4	15.42% (+0.37)	―
May 07, 2024	2024 (Q1)	-2.04 / -2.05	-2.4	14.58% (+0.35)	―
Feb 08, 2024	2023 (Q4)	-2.12 / -2.03	-2.4	15.42% (+0.37)	―
Nov 02, 2023	2023 (Q3)	-2.33 / -2.13	-2.8	23.93% (+0.67)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CRIS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 06, 2025	$1.42	$1.46	+2.82%
Aug 05, 2025	$1.60	$1.67	+4.37%
May 06, 2025	$2.45	$2.19	-10.61%
Mar 31, 2025	$2.32	$2.10	-9.48%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Curis Inc (CRIS) report earnings?

Curis Inc (CRIS) is schdueled to report earning on Mar 17, 2026, Before Open (Confirmed).

What is Curis Inc (CRIS) earnings time?

Curis Inc (CRIS) earnings time is at Mar 17, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CRIS EPS forecast?

CRIS EPS forecast for the fiscal quarter 2025 (Q4) is -0.45.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing